The GLP-1 Gold Rush: What’s at Stake for DIY Investors?

The biotech sector has been abuzz with excitement over a new class of drugs that mimic the action of glucagon-like peptide-1 (GLP-1) hormones. These medications have taken the market by storm, drawing investors to capitalize on this trend. Two companies, Eli Lilly and Viking Therapeutics, are leading contenders in the GLP-1 space.

Recent breakthroughs have expanded the addressable markets for these drugs beyond just diabetes and weight management. Companies are now exploring new indications, such as obstructive sleep apnea (OSA) and metabolic dysfunction-associated steatohepatitis. The potential for growth is vast, but the market landscape is becoming increasingly crowded.

Eli Lilly has been a stalwart in this space, with its tirzepatide medication driving massive revenue. Tirzepatide is approved for diabetes, weight loss, and OSA, generating $23 billion in the second quarter alone. Sales of Mounjaro (the brand name for tirzepatide in the diabetes market) have soared 91% year over year to $9.9 billion, while Zepbound’s (tirzepatide’s brand in weight management) revenue was $4.9 billion, up 46% compared to the previous period.

Eli Lilly has a deep pipeline of other promising products, including retatrutide, which posted impressive phase 3 clinical trial results in diabetes and weight loss. Approval for retatrutide is expected in the first quarter of 2027, solidifying Eli Lilly’s position as a leader in this market.

Viking Therapeutics is gunning for the top spot with its own GLP-1 candidates. VK2735, a dual GLP-1 and GIP agonist, has shown impressive results in phase 2 studies, with a mean weight loss of up to 14.7% in 13 weeks. The company plans to start late-stage trials for an oral formulation by year-end, which could be a game-changer.

For DIY investors, the GLP-1 gold rush is likely to continue, but it’s also becoming increasingly crowded and competitive. Eli Lilly has the advantage of a strong track record and deep pipeline, while Viking Therapeutics is still in the clinical-stage biotech category. As such, investors will need to carefully weigh their options and consider which company is more likely to deliver long-term value.

The GLP-1 market represents a broader shift towards personalized medicine and targeted therapies, which could fundamentally change the way we approach disease treatment. This trend has far-reaching implications, extending beyond just biotech stocks. Investors would do well to keep a close eye on this space – not just for short-term gains, but also for long-term potential.

In recent memory, few instances have arisen where biotech companies have managed to challenge established leaders in the GLP-1 market. Eli Lilly itself has steadily built its position over the years through innovative products and strategic partnerships. However, Viking Therapeutics’ ability to replicate this success remains uncertain.

Investors should be aware that the biotech sector is notorious for its boom-and-bust cycles. While it’s easy to get caught up in new discoveries and breakthroughs, it’s equally important to remain grounded in reality. Companies like Eli Lilly and Viking Therapeutics will need to deliver on their promises – not just in terms of product efficacy but also financial performance.

In the end, the GLP-1 gold rush is a wild ride that’s far from over. While Eli Lilly has the advantage of experience and a strong track record, Viking Therapeutics is a dark horse worth keeping an eye on. For DIY investors, it’s essential to stay vigilant and adapt to changing market conditions – after all, in biotech, yesterday’s winner can quickly become today’s loser.